Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.64 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.62 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30254972 | 1.00 | KMT2A (0.69) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL31511903 | 0.93 | MEN1 (0.76) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL4656453 | 0.93 | MEN1 (0.76) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL10829584 | 0.90 | TSHR (0.63) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL23849525 | 0.88 | NPC1 (0.58) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL4731182 | 0.86 | NPC1 (0.86) | KMT2AMEN1NPC1RAB9AHPGD | |
| Davidigenin SCHEMBL750182 | 0.85 | CYP19A1 (0.70) | KMT2AMEN1NPC1RAB9AHPGD | |
| Davidigenin SCHEMBL30291870 | 0.85 | CYP19A1 (0.70) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL3658652 | 0.83 | NPC1 (0.64) | KMT2AMEN1NPC1RAB9AHPGD | |
| SCHEMBL1734687 | 0.83 | NPC1 (0.52) | KMT2AMEN1NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281451-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. | 2025-09-11 | — | — | US | claimed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | claimed |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) | 2021-11-25 | — | — | US | claimed |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-11-07 | — | — | US | claimed |
| EP-1784201-B1 | PHYSIOLOGICALLY ACTIVE COMPOSITION AGAINST DIABETES | PHYTOMEDICS INC (US) | 2010-10-20 | — | — | EP | claimed |
| US-20090142425-A1 | Physiologically active composition | PHYTOMEDICS INCORPORATED | 2009-06-04 | — | — | US | claimed |
| EP-1996212-A2 | COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS | Rutgers, The State University of New Jersey (US) | 2008-12-03 | — | — | EP | claimed |
| WO-2007109217-A2 | COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS | RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070224301-A1 | Compounds from an extract of Artemisia and methods for treating disorders | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2007-09-27 | — | — | US | claimed |
| EP-4622640-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | Brightseed, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250281451-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. | 2025-09-11 | — | — | US | disclosed |
| WO-2024112947-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | BRIGHTSEED, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20230293614-A1 | COMPOSITIONS AND METHODS OF TREATING UPS-ASSOCIATED DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-21 | — | — | US | disclosed |
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-09 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| US-20070092551-A1 | Therapeutic agent | TAKARA BIO INC. (JP) | 2007-04-26 | — | — | US | disclosed |
| WO-2006010560-A3 | PHYSIOLOGICALLY ACTIVE COMPOSITION | BIOGHURT BIOGARDE GMBH & CO KG (DE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006010560-A8 | PHYSIOLOGICALLY ACTIVE COMPOSITION | BIOGHURT BIOGARDE GMBH & CO KG (DE) | 2006-03-30 | — | — | WO | disclosed |
| EP-1623704-A1 | THERAPEUTIC AGENT | TAKARA BIO INC. (JP) | 2006-02-08 | — | — | EP | disclosed |
| WO-2006010560-A2 | PHYSIOLOGICALLY ACTIVE COMPOSITION | CARGILL, INCORPORATED (US) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224301-A1 | Compounds from an extract of Artemisia and methods for treating disorders | PDK2, PCK2, DUSP2 | KMT2A 1873/4885MEN1 3925/4885NPC1 4179/4885 |
| US-20190337916-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | KMT2A 910/4885MEN1 1539/4885NPC1 3334/4885 |
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | GCKR, G6PC1, GPR119 | KMT2A 3878/4885MEN1 1345/4885NPC1 609/4885 |
| US-20070092551-A1 | Therapeutic agent | FABP4, GPR119, IAPP | KMT2A 4418/4885MEN1 2467/4885NPC1 361/4885 |
| US-20210363121-A1 | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | NOTCH1, DNER, NOTCH2 | KMT2A 910/4885MEN1 1539/4885NPC1 3334/4885 |
| US-20250281451-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF | PER2, PYGB, CRY2 | KMT2A 1441/4885MEN1 3929/4885NPC1 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.